Bioventix (BVXP) AI Stock Analysis

• Market Cap: £96.66M
• Dividend Yield: 8.33%
• Average Volume (3M): 7.85K
• Price to Earnings (P/E): 6.9
• Beta (1Y): 0.64
• Revenue Growth: -3.61%
• EPS Growth: -6.35%
• Country: UK
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.68
• Shares Outstanding: 5,224,860
• 10 Day Avg. Volume: 9,152
• 30 Day Avg. Volume: 7,851
• PEG Ratio: -2.93
• Price to Book (P/B): 12.43
• Price to Sales (P/S): 10.95
• P/FCF Ratio: 20.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.36
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: 1,800.00 p ▲(0.00% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).

Positive Factors

Recurring B2B licensing model

Bioventix’s core B2B model—licensing high‑affinity monoclonal antibodies and selling reagent supplies—creates long-duration, recurring revenues and royalties tied to diagnostic test lifecycles. This provides predictable cash flows and durable customer lock-in once assays are validated.

Negative Factors

Recent decline in cash generation

A material drop in free cash flow reduces internal funding for R&D, commercial support and dividends. If the FCF contraction persists it can constrain growth investments and the company’s ability to respond to competitive or regulatory shifts over the next several months.

Bioventix Business Overview & Revenue Model

Company Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious dise...

Read more

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious dise...

How the Company Makes Money

Bioventix primarily makes money by licensing and supplying monoclonal antibody reagents to major in-vitro diagnostics and assay manufacturers. Its core revenue model is business-to-business: Bioventix develops proprietary antibodies against specif...

Read more

Bioventix primarily makes money by licensing and supplying monoclonal antibody reagents to major in-vitro diagnostics and assay manufacturers. Its core revenue model is business-to-business: Bioventix develops proprietary antibodies against specif...

Bioventix Financial Statement Overview

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	12.54M	13.12M	13.61M	12.82M	11.72M	10.93M
Gross Profit	11.53M	11.92M	12.68M	11.86M	10.87M	9.98M
EBITDA	9.54M	10.17M	10.74M	10.20M	9.42M	8.22M
Net Income	7.44M	7.58M	8.10M	8.37M	7.67M	6.73M
Balance Sheet
Total Assets	13.03M	12.86M	13.73M	13.28M	13.12M	12.91M
Cash, Cash Equivalents and Short-Term Investments	5.30M	5.08M	6.00M	5.72M	6.13M	6.49M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.99M	1.31M	1.73M	1.22M	1.30M	1.09M
Stockholders Equity	11.04M	11.55M	12.00M	12.06M	11.82M	11.82M
Cash Flow
Free Cash Flow	7.92M	7.01M	8.33M	7.89M	7.55M	6.11M
Operating Cash Flow	7.96M	7.03M	8.34M	7.90M	7.56M	6.37M
Investing Cash Flow	-32.75K	173.16K	186.06K	90.51K	-11.76K	-259.83K
Financing Cash Flow	-7.76M	-8.12M	-8.25M	-8.30M	-7.92M	-7.69M

Bioventix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1800.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Positive. The current price of 1800 is above the 20-day moving average (MA) of 1476.81, above the 50-day MA of 1548.38, and below the 200-day MA of 1976.18, indicating a neutral trend. The MACD of 66.01 indicates Negative momentum. The RSI at 76.00 is Negative, neither overbought nor oversold. The STOCH value of 85.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BVXP.

Bioventix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	75 Outperform	£96.66M	6.86	65.83%	8.33%	-3.61%	-6.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FAB	44 Neutral	£18.13M	-9.67	-210.32%	―	-11.43%	23.40%
AVCT	42 Neutral	£306.18M	-1.74	-361.23%	―	―	―
4BB	41 Neutral	£79.75M	-4.89	-63.53%	―	198.49%	-26.66%
OBD	40 Underperform	£8.15M	-0.25	-316.67%	―	72.17%	79.03%
APTA	40 Underperform	£17.56M	-6.19	-213.66%	―	39.88%	81.33%

Bioventix Corporate Events